a multicentre double blind trial is underway to evaluate aminoglutethimide ( ag ) ( orimeten , ciba ) 1.000 mg/day with hydrocortisone ( hc ) 20-40 mg/day versus placebo for adjuvant treatment of post menopausal patients with histologically confirmed stage ii breast cancer .
C0002555
aminoglutethimide
C0591920
orimeten